In this paper, we report the crystal growth of four cocrystals of furosemide (4-chloro-2-[(2-furanylmethyl)amino]-5-sulfamoylbenzoic acid), a loop diuretic drug used for the treatment of hypertension and edemas, prepared with <i>p</i>-aminobenzoic acid, nicotinamide, and isonicotinamide as coformers. We present four new crystal structures and elucidate the intermolecular interactions present in the cocrystals. The structures display interesting supramolecular chemistry: a number of different synthons, as well as short strong hydrogen bonds with partial proton transfer and indications of proton disorder. Using powder X-ray diffraction, solid state NMR, and thermal analysis, we provide evidence for the preparation of bulk samples of two comp...
The use of cocrystallisation as a tool to improve the pharmaceutical profile of the low-solubility d...
Pharmaceutical cocrystals of nonsteroidal anti-inflammatory drugs diflunisal (DIF) and diclofenac (D...
Cocrystallization of an active pharmaceutical ingredient (API) with a cocrystal former (co-former) i...
In this paper, we report the crystal growth of four cocrystals of furosemide (4-chloro-2-[(2-furanyl...
In this paper, we report the crystal growth of four cocrystals of furosemide (4-chloro-2-[(2-furanyl...
Four new crystal structures of pharmaceutical molecule furosemide with GRAS coformers are reported a...
The design and synthesis of stable solid-state pharmaceutical cocrystals of diuretic drug furosemide...
Furosemide is a loop diuretic drug marketed in solid form which suffers from low solubility and low ...
Furosemide (FS), a loop diuretic drug commonly used for the treatment of hypertension and edema, exh...
Multicomponent solid forms of the BCS class IV drug furosemide (FSM) were obtained upon liquid assis...
Furosemide is a loop diuretic drug marketed in solid form which suffers from low solubility and low ...
Molecular cocrystals are of growing interest in pharmaceutics for their improved physicochemical pro...
Co-crystallization is a promising approach to improving both the solubility and the dissolution rate...
In the last years, the design and synthesis of co-crystals containing active pharmaceutical ingredi...
Niclosamide (NCL) is an anthelmintic BCS class II drug of low solubility and high permeability. Phar...
The use of cocrystallisation as a tool to improve the pharmaceutical profile of the low-solubility d...
Pharmaceutical cocrystals of nonsteroidal anti-inflammatory drugs diflunisal (DIF) and diclofenac (D...
Cocrystallization of an active pharmaceutical ingredient (API) with a cocrystal former (co-former) i...
In this paper, we report the crystal growth of four cocrystals of furosemide (4-chloro-2-[(2-furanyl...
In this paper, we report the crystal growth of four cocrystals of furosemide (4-chloro-2-[(2-furanyl...
Four new crystal structures of pharmaceutical molecule furosemide with GRAS coformers are reported a...
The design and synthesis of stable solid-state pharmaceutical cocrystals of diuretic drug furosemide...
Furosemide is a loop diuretic drug marketed in solid form which suffers from low solubility and low ...
Furosemide (FS), a loop diuretic drug commonly used for the treatment of hypertension and edema, exh...
Multicomponent solid forms of the BCS class IV drug furosemide (FSM) were obtained upon liquid assis...
Furosemide is a loop diuretic drug marketed in solid form which suffers from low solubility and low ...
Molecular cocrystals are of growing interest in pharmaceutics for their improved physicochemical pro...
Co-crystallization is a promising approach to improving both the solubility and the dissolution rate...
In the last years, the design and synthesis of co-crystals containing active pharmaceutical ingredi...
Niclosamide (NCL) is an anthelmintic BCS class II drug of low solubility and high permeability. Phar...
The use of cocrystallisation as a tool to improve the pharmaceutical profile of the low-solubility d...
Pharmaceutical cocrystals of nonsteroidal anti-inflammatory drugs diflunisal (DIF) and diclofenac (D...
Cocrystallization of an active pharmaceutical ingredient (API) with a cocrystal former (co-former) i...